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Abstract
Background: Oral vancomycin (125 mg qid) is recommended as treatment of severe Clostridium difficile infection
(CDI). Higher doses (250 or 500 mg qid) are sometimes recommended for patients with very severe CDI, without
supporting clinical evidence. We wished to determine to what extent faecal levels of vancomycin vary according to
diarrhoea severity and dosage, and whether it is rational to administer high-dose vancomycin to selected patients.
Methods: We recruited hospitalized adults suspected to have CDI for whom oral vancomycin (125, 250 or 500 mg qid)
had been initiated. Faeces were collected up to 3 times/day and levels were measured with the AxSYM fluorescence
polarization immunoassay.
Results: Fifteen patients (9 with confirmed CDI) were treated with oral vancomycin. Patients with ≥4 stools daily
presented lower faecal vancomycin levels than those with a lower frequency. Higher doses of oral vancomycin
(250 mg or 500 mg qid) led to consistently higher faecal levels (> 2000 mg/L), which were 3 orders of magnitude
higher than the MIC90 of vancomycin against C. difficile. One patient receiving 125 mg qid had levels below 50 mg/L
during the first day of treatment.
Conclusions: Faecal levels of vancomycin are proportional to the dosage administered and, even in patients with
increased stool frequency, much higher than the MIC90. Patients given the standard 125 mg qid dosage might
have low faecal levels during the first day of treatment. A loading dose of 250 mg or 500 mg qid during the first
24-48 hours followed by the standard dosage should be evaluated in larger studies, since it might be less
disruptive to the colonic flora and save unnecessary costs.
Background
Clostridium difficile infection (CDI) is the main cause of
nosocomial diarrhoea in industrialized countries.
Recently, an increase in CDI incidence was observed in
North America and Europe due to the emergence of an
apparent toxin hyper-producing strain (NAP1/BI/027)
[1-6]. For many years, metronidazole was preferred to
vancomycin as the first-line treatment of CDI because
of its lower cost, lower selection pressure for the emer-
gence of vancomycin-resistant pathogens, and because it
was considered as effective as vancomycin for most
patients [7-12]. Oral vancomycin was recommended
only for the most severe cases and for those relapsing
after a course of metronidazole, based on its extremely
high faecal levels, which are several hundred times
higher than the MIC90 of vancomycin against C. difficile.
Recently, this paradigm has been altered by reports of
high rates of treatment failures and recurrences with
metronidazole treatment and by randomized trials
showing a potential advantage of oral vancomycin for
severe cases [13,14].
The optimal dosage of oral vancomycin has not been
well delineated. An underpowered study compared two
different dosages (125 vs. 500 mg qid) without showing
an impact on clinical outcomes [15]. Nevertheless, the
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patients with ileus, megacolon or hypotension [16]. The
European Society of Clinical Microbiology and Infec-
tious Diseases recommends giving the standard vanco-
mycin dosage (125 mg qid) when oral therapy is
possible for severe CDI but giving 500 mg qid via a
nasogastric tube when oral therapy is impossible [17]. It
would be very difficult to test such a strategy in clinical
trials. However, pharmacokinetic studies of faecal vanco-
mycin levels (as a proxy for colonic levels) can shed
light on this debate. Early pharmacokinetic studies used
bioassays in which dilutions of faecal material were
incubated with an assay organism (Bacillus subtilis)o f
known sensitivity [18-20]. Subsequent work used a
fluorescence polarization immunoassay [21,22] but only
one documented sequential measurements in a few
patients [21]. Some used Vancocin
® capsules, while
many hospitals now administer orally generic IV vanco-
mycin. To determine whether faecal levels of vancomy-
cin vary according to stool frequency and dosage
administered, we conducted a pharmacokinetic study of
generic IV vancomycin administered orally to patients
with suspected CDI.
Methods
Study design
A prospective observational study was conducted at the
Centre Hospitalier Universitaire de Sherbrooke (CHUS),
a 686-bed tertiary-care centre, from January to
November 2009. Inpatients were invited to participate if
(1) they were ≥ 18 years of age; (2) they had experienced
three or more loose stools within the previous 24 hours;
(3) they were already receiving oral vancomycin (using
the IV formulation) for a suspicion of CDI, as prescribed
by their attending physician. Patients unable to consent
and/or who received vancomycin for less than 48 hours
were excluded.
The institutional review board of the CHUS had
approved our study protocol. Consenting patients were
followed as long as they were receiving oral vancomycin
or up to hospital discharge, whichever occurred first.
Stool samples were collected up to three times per day
for the first three days and daily for the remaining
11 days, and stored at -80°C until testing. Blood samples
were drawn on days 1 and 3 to perform vancomycin
serum levels. Patients were stratified in two groups
according to stool frequency during the initial 72 hours
of the treatment: ≥4o r≤3 stools per day (this cut-off
corresponded to the median value). Stool frequency was
obtained from intestinal habits forms completed pro-
spectively by patients’ nurses as well as from nurses’
notes in medical records. Patients were considered posi-
tive for CDI if they had either (1) a positive result with
the cytotoxicity assay; (2) C. difficile detected by toxi-
genic culture; or (3) pseudomembranes evidenced by
endoscopy. The standard vancomycin dosage referred to
an intake of 125 mg qid. The other two regimens (250
and 500 mg qid) were considered higher doses. When
two episodes of CDI occurred in the same patient more
than 3 months apart, they were considered distinct
events; an episode occurring within 3 months of a prior
one was considered a relapse.
Vancomycin assay
Faecal samples were diluted 1:40 in saline as to obtain
values within the linear portion of the AxSYM assay
(1.0 to 100 mg/L) and to reduce the impact of faecal
material on the assay. This was further diminished by
centrifuging 1 ml aliquots of the solution at 17,000 g for
10 minutes. The supernatant was then filtered through a
0.45 μm filter and sent to the clinical laboratory where
vancomycin levels were determined using a fluorescence
polarization assay on the AxSYM (Abbott, Abbott Park,
I l l i n o i s ) .T h eA x S Y Ma s s a yw a sa l s ou s e dt om e a s u r e
serum levels, as recommended by the manufacturer.
Microbiological analyses
The first faecal sample was homogenized in BHI broth
and spores were selected after killing all vegetative cells
by mixing the faecal suspension with an equal volume
of ethanol (50% final concentration) and incubating at
room temperature for 45 minutes. The treated speci-
mens were inoculated onto C. difficile moxalactam nor-
floxacin selective agar plates (CDMN, Oxoid, Nepean,
Canada) supplemented with 5% sheep blood, 1 mM gly-
cine and 0.1% taurocholic acid and were incubated anae-
robically at 37°C for 24-48 hours. C. difficile
identification was confirmed by colony morphology, dis-
tinct odour, and by a specific PCR reaction targeting the
triose phosphate isomerase (tpi) gene [23].
Strain typing
PCR ribotyping was performed using primers described
previously with some modifications [24,25]. DNA frag-
ments were separated through a 5% polyacrylamide gel
and visualized under UV light after ethidium bromide
staining. Profiles were analyzed with GelCompar II
(Applied Maths) software.
Data analysis
Data were analyzed using SAS, version 9.1.3 (Cary,
North Carolina). Medians and ranges were reported in
figures. Median faecal concentrations of vancomycin
were compared using the Mann-Whitney test. Propor-
tions were compared with the Pearson x
2 test or the
Fisher exact test when numbers were small.
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A total of 19 patients were enrolled in the study. Four
patients were subsequently excluded: two because they
received vancomycin for only one day after recruitment,
and two others who had less than 2 stool specimens col-
lected during their hospital stay. The final study sample
included 15 patients (nine women and six men) with a
median age of 63 (range: 43-99) years. Oral vancomycin
was prescribed every six hours in all patients. Initial
dosages (as selected by the attending physicians) were:
125 mg (n = 9), 250 mg (n = 4), and 500 mg (n = 2).
Five patients had their dosage modified during their
hospital stay. No patient experienced a CDI relapse
within 90 days of enrolment.
Nine patients had a confirmed CDI (three had a posi-
tive cytotoxicity assay, four had evidence of pseudo-
membranous colitis, and two had both) while in the
other six the diagnosis could not be confirmed. Toxi-
g e n i cc u l t u r e sw e r ep o s i t i v eo n l yi np a t i e n t si nw h o m
the diagnosis had been proven by other methods. Based
on PCR ribotyping, none of the cultured strains corre-
sponded to the hypervirulent strain (ribotype 027). Of
these nine patients, six had a peak leukocyte count
greater than 15 × 10
9/L, including three who were
admitted to the ICU for severe CDI, and one who devel-
oped acute renal failure. Five were aged 60 years or
more.
Faecal levels
We compared faecal levels of vancomycin in patients
with or without CDI confirmation, and found no sta-
tistically significant differences at any day of therapy
(data not shown). Additionally, baseline data were
similar in both groups (Table 1). Therefore, the rest of
the analyses included all 15 patients, regardless of their
CDI diagnosis. Day-to-day median faecal levels of van-
comycin and ranges achieved according to dosage are
illustrated in Figure 1. There were substantial varia-
tions between individual patients. Higher doses of oral
vancomycin (250 mg or 500 mg qid) led to consistently
higher faecal levels than the standard dose of 125 mg
qid (Figure 1). Such differences were statistically signif-
icant from day 2 to day 4 inclusively. With the 250 mg
qid dosage, faecal levels were generally above 2000
mg/L while with the 500 mg qid dosage levels were
generally above 4000 mg/L. With the two higher
dosages, faecal levels were always above 500 mg/L,
even during the first few days of therapy, while with
t h e1 2 5m gq i dd o s a g es o m ep a t i e n t si n i t i a l l yh a d
levels below this threshold, and one had levels at 15
and 33 mg/L on day 1.
As shown in Figure 2, patients with higher (≥4 per day)
stool frequency had lower vancomycin faecal levels, and
the difference was statistically significant on days 4 and 5.
These two groups did not differ with regard to the dosage
and treatment duration used by their attending physi-
cians: of 267 doses administered to patients with ≥4
stools per day, 123 (43%) were 250 mg or 500 mg while
of 187 doses administered to patients with ≤3 stools per
day, 91 (49%) were 250 mg or 500 mg] (p = 0.4). Average
duration of treatment was 7 days (SD ± 4.1) for patient
with ≥4 stools per day and 10.4 days (SD ± 4.5) in
patients with ≤3 stools per day (p = 0.15). The patient
with levels below 50 mg/L on day 1 was categorized as
having mild diarrhoea but was not in ileus.
Three patients had their faecal levels measured after
treatment completion. One had been in ileus and still
had high levels (1422 mg/L) 48 hours after oral vanco-
mycin was stopped. Two other patients had low levels
on the day after their treatment was discontinued
(23 and 38 mg/L).
Serum levels
Serum samples were collected on day 1 and 3 after
recruitment in 11 patients (two did not consent to pro-
vide a blood sample and two others received IV vanco-
mycin for some other reason and were excluded). Serum
concentrations ranged from 0 to 0.77 mg/L. Patients
receiving higher dosage and/or with renal failure did not
exhibit higher serum levels (data not shown).
Discussion
Vancomycin has long been used only as a second-line
treatment of CDI due to its high cost, if administered as
Table 1 Baseline characteristics in patients with and
without confirmed CDI diagnosis
N (%) or median (IQR)
Variable CDI-positive
(n =9)
CDI-negative
(n = 6)
Age (years) 62 (50-86) 64 (59-65)
Peak creatinine (μmol/L)
< 100 8 (89) 6 (100)
100-199 0 0
≥200 1 (11) 0
Peak leukocyte count × 10
9/L
< 10.0 0 1 (17)
10.0 - 19.9 2 (22) 2 (22)
≥20.0 7 (78) 3 (50)
Number of stools/day 4 (0-6) 5 (3-6)
Fever (first 48 hours) 3 (33) 5 (83)
Ileus 1 (11) 0
Initially prescribed dosage
125 mg 5 (56) 4 (67)
250 mg 3 (33) 1 (17)
500 mg 1 (11) 1 (17)
Days of treatment 6 (5-15) 5 (4-10)
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® capsule. Many hospitals now reduce their
acquisition costs by administering orally the generic for-
mulation of intravenous vancomycin, which is 10-fold
cheaper. Our results support this approach and docu-
ment that the faecal levels obtained with the IV formu-
lation are as high as those measured in patients who
had received the Vancocin
® capsule in previous studies
[20,21].
As could have been predicted from the product’s lim-
ited absorption, faecal levels of vancomycin increased in
proportion with the dosage administered. For most of
the duration of therapy, faecal levels achieved with the
h i g h e rd o s a g ea r ev e r yu n l i k e l yt ob em o r ee f f e c t i v e
than those obtained with the standard 125 mg qid
dosage, which themselves were often 500-1000 times
higher than the MIC90 (1.0 mg/L) of vancomycin against
C. difficile [26-29].
The faecal levels of vancomycin were influenced by
stool frequency. Even if they were administered similar
dosages of vancomycin, patients with ≥ 4 stools per day
had lower levels compared to their counterparts, but the
former’s faecal levels were nevertheless consistently 100
to 1000 fold greater than the MIC90.S u c hf i n d i n g sa r e
consistent with a higher output of loose stools resulting
in some dilution of the vancomycin, but this would
probably not be clinically relevant.
One of our patients receiving 125 mg qid had low fae-
cal levels (only 15 and 33 mg/L) on day 1, as did some
patients in a previous study [21]. Therefore it seems to
us, based on our data and published literature, that for
most CDI patients the only rationale for giving a higher
dosage would be as a loading dose (250 or 500 mg qid)
during the first 24-48 hours, especially in patients with
some ileus for whom the delivery of orally administered
Figure 1 Median faecal vancomycin levels achieved with different oral vancomycin dosages. * Bars represent range. When no range is
indicated, a single specimen was analyzed.
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there is little rationale for giving more than 125 mg qid,
unless the patient has very severe ileus: neither our
study nor previous work specifically addressed this sub-
population of CDI cases. However, before modifying
clinical practices, additional studies are required to eval-
uate lower dosages, in the hope that they would be as
effective against C. difficile while being less destructive
for the normal colonic flora. Indeed, faecal levels of van-
comycin with the 125 mg qid dosage are often higher
than the MIC90 of this drug against Bacteroides and Pre-
votella spp (64-256 mg/L) and consequently might alter
the normal colonic flora and favour relapses [30-32].
In patients receiving orally administered vancomycin,
serum levels were always below 1 mg/L, even in patients
given the highest 500 mg qid dosage and in those with
renal failure. These low serum levels are irrelevant with
regard to potential nephrotoxicity or ototoxicity. A
handful of case reports have demonstrated considerable
systemic absorption (within the 5-10 mg/L range) after
oral administration of vancomycin in patients who had
either severe renal disease or were receiving high doses
of oral vancomycin (250 or 500 mg qid) [33-36]. Only
one published case reported a patient with significant
systemic absorption and normal renal function but the
patient suffered from severe graft-versus-host disease of
the gastrointestinal tract [33]. Our study is the largest to
quantify the systemic absorption of oral vancomycin.
Our data suggest there is no need to monitor vancomy-
cin serum levels in patients receiving oral vancomycin
for CDI, unless they receive high doses for prolonged
periods with ileus and/or end-stage renal failure, as sta-
ted in the IDSA guidelines [16].
Our study had limitations. Its small sample size lim-
ited its power to detect statistically significant differ-
ences between subgroups. Some of our patients were
Figure 2 Median faecal vancomycin concentrations achieved in patients stratified according to their stool frequency. * Bars represent
range. When no range is indicated, a single specimen was analyzed.
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was on vancomycin pharmacokinetics, we elected to
include all patients at the onset of their vancomycin pre-
scription in order to have the most samples possible
rather than wait for CDI confirmation. In the absence of
universally accepted criteria, we chose stool frequency
to evaluate the impact of such a “diluting factor” on the
faecal vancomycin levels but admittedly this is an imper-
fect measure of diarrhoea severity.
Conclusions
Faecal levels of vancomycin are roughly proportional to
the dosage administered and even in patients with high
stool frequency are consistently 100 to 1000 times
higher than the MIC90. Patients given the standard
125 mg qid dosage might have low faecal levels during
the first 24 hours of treatment. A loading dose of
250 mg or 500 mg qid during the first 24-48 hours
followed by the standard dosage should be evaluated in
larger pharmacokinetics studies, since it might be less
disruptive to the colonic flora and save unnecessary
costs.
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